{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~17 mi. (Lecco, Italy, +383 more cities)
facility
ASST DI LECCO; Oncologia Medica
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
city
~23 mi. (Bellinzona, Switzerland, +93 more cities)
facility
Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)
drug
belzutifan, +1 more drug
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~23 mi. (Bellinzona, Switzerland, +150 more cities)
facility
Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1921)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~23 mi. (Bellinzona, Switzerland, +105 more cities)
facility
Ospedale Regionale di Bellinzona e Valli ( Site 1407)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~23 mi. (Bellinzona, Switzerland, +76 more cities)
facility
Ospedale Regionale Bellinzona e Valli ( Site 2203)
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
city
~23 mi. (Bellinzona, Switzerland, +15 more cities)
facility
Ospedale Regionale di Bellinzona e Valli
biomarker
ARID1A Loss, +125 more biomarkers
drug
elimusertib, +1 more drug
drug type
immunotherapy, +1 more type
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
city
~30 mi. (Via Manzoni, Italy, +31 more cities)
facility
IRCCS istituto Clinico Humanitas U.O. di Oncologia ed Ematologia
condition
Diffuse Large B-Cell Lymphoma, +1 more condition
drug
ibrutinib, +1 more drug
drug type
chemotherapy, +2 more types
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~37 mi. (Monza, Italy, +262 more cities)
facility
ASST DI MONZA; Oncologia Medica
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type